BrainStorm gets FDA fast-track status for ALS stem cell therapy – Reuters
|
BrainStorm gets FDA fast-track status for ALS stem cell therapy
Reuters TEL AVIV (Reuters) – Israel's BrainStorm Cell Therapeutics said the U.S. Food and Drug Administration has designated its adult stem cell treatment as a "fast-track" product for the treatment of amyotrophic lateral sclerosis (ALS). BrainStorm's … |
